Recursion and Exscientia Merge to Form Global AI-Driven Drug Discovery Powerhouse

Merger Announcement and Strategic Vision

Recursion Pharmaceuticals, Inc. and Exscientia plc have entered into a definitive agreement to merge, forming a global technology-enabled drug discovery company 1

1

. This strategic move aims to combine Recursion's large-scale automated wet-labs and massive proprietary biological datasets with Exscientia's small molecule drug design capabilities and AI-driven precision medicine platform 2

2

.

Deal Structure and Financial Details

The all-stock transaction is valued at approximately $1 billion, with Recursion set to acquire all outstanding Exscientia shares. Exscientia shareholders will receive 0.6406 shares of Recursion Class A common stock for each Exscientia ADS held 1

1

. Upon completion, Recursion shareholders will own about 67% of the combined company, while Exscientia shareholders will hold the remaining 33% 2

2

.

Leadership and Governance

The merged entity will be led by Recursion's co-founder and CEO, Chris Gibson, who will serve as the Chief Executive Officer. Andrew Hopkins, founder and CEO of Exscientia, will join Recursion's Board of Directors 1

1

. The combined company will maintain a significant presence in both the United States and the United Kingdom, leveraging the strengths of both organizations 2

2

.

Technological Synergies and Capabilities

The merger is expected to create a powerhouse in AI-driven drug discovery, combining Recursion's proprietary AI-enabled drug discovery platform with Exscientia's precision medicine capabilities 1

1

. This integration aims to enhance the ability to identify novel drug candidates, optimize molecules, and potentially accelerate the drug development process 2

2

.

Financial Position and Growth Prospects

Recursion recently reported its second quarter 2024 financial results, showcasing a strong cash position of $441 million 3

3

. The company has been making significant strides in its pipeline development, with multiple programs advancing through clinical trials 4

4

.

Industry Impact and Future Outlook

This merger represents a significant consolidation in the AI-driven drug discovery sector, potentially setting a new standard for technology-enabled pharmaceutical research. The combined company is expected to have enhanced capabilities in target identification, lead optimization, and clinical development, potentially accelerating the timeline from discovery to market for new therapeutics 1

1

2

2

.

Closing Conditions and Timeline

The transaction is subject to customary closing conditions, including approval by shareholders of both companies and regulatory clearances. The merger is expected to close in the first quarter of 2025, marking a new era in AI-powered drug discovery and development 1

1

2

2

.